Clinical Trials

Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. The purpose of this study is to examine the density of the lung as measured by chest computed tomography (CT) and determine if existing emphysema predicts changes in the rate of subsequent emphysema or changes in CT, serum or plasma biomarkers of interest. The overarching goal is to develop biomarkers that can be used in interventional trials since lung function changes do not typically inform disease progression in AATD.

Do you or your child have a lung disease? This study will investigate the genes involved in the breathing process and in the development of lung diseases such as asthma or sarcoidosis to improve understanding of the role they play. To participate in this study, you or your child must be between 2 and 90 years old. This study is located in Bethesda, Maryland, at the NIH Clinical Center.

This study is being done to determine the mechanism(s) contributing to the onset of symptoms (i.e. shortness of breath and/or palpitations) as well as changes in right heart structure in patients with Tetralogy of Fallot (TOF).

The goal of this project is to improve risk-stratification for patients who present to the emergency department (ED) with syncope (transient loss of consciousness), in order to better delineate which patients require admission and which can be safely discharged home. Syncope and pre-syncope (the sensation of impending loss of consciousness) are common reasons to present to the ED, representing over 1.3 million visits per year in the United States.

Do you have cancer that is treated with something called Bruton's tyrosine kinase inhibitors or BKTi? In this study, researchers want to learn more about Bruton's tyrosine kinase inhibitors, which are often used to treat cancer, affect the heart. You can participate in this study if you are currently receiving or will be receiving Bruton's tyrosine kinase inhibitors. This study is taking place at the National Institutes of Health Clinical Center in Bethesda, Maryland.

The proposed research is to address the accessibility and affordability of technology to capture symptomatic and asymptomatic cardiac events via Long-Term Continuous Electrocardiogram Monitoring (LTCM), and to provide physicians with full access to their patients' recorded data in a timely manner.

Are you a Minnesota resident with hypertrophic cardiomyopathy? This study aims to find out how common it is for people with hypertrophic cardiomyopathy to also have sleep apnea. Hypertrophic cardiomyopathy is a disease that causes the heart muscle to thicken. Participants will also wear a heart rhythm monitor to help researchers learn whether sleep apnea is linked to arrhythmia. The study seeks healthy volunteers as well as participants in the Hypertrophic Cardiomyopathy Registry. To participate in this study, you must not have had a catheter ablation procedure to treat atrial fibrillation, had surgery to replace your heart valves, or been treated for sleep apnea. The study is located in Rochester, Minnesota.

Do you have heart disease that requires an ICD to prevent sudden cardiac arrest? This study aims to learn what signs distinguish patients who have a higher risk of an arrhythmia that leads to sudden cardiac arrest. Researchers plan to track patients with a recent ICD replacement for 10 years. To participate in this study, you must be between 18 and 85 years old. This study is located in Washington, D.C.; Baltimore, Maryland; and Richmond, Virginia.

Do you know someone who will be having heart surgery? This study aims to identify what genetic patterns might cause atrial fibrillation and other adverse events that happen after heart surgery. To participate in this study, you must be between 20 and 90 years old. The study is in three locations in Massachusetts and Texas.

Does your developing baby have a heart defect? Have you had a stillborn baby? This study tests a new technology to measure fetal heart activity and find possible problems early. These problems include fetal arrhythmia and conduction disorders such as Brugada syndrome. To participate in this study, you must be at least 18 years old and pregnant, and have one of five high-risk complications of pregnancy: a fetus with a major congenital heart defect, hydrops, or gastroschisis; a previous unexplained stillbirth; or twins who share a placenta. This study is located in Madison and Milwaukee, Wisconsin.